News for Syndax Pharmaceuticals, Inc. (SNDX)

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NSNDX.OQ - Syndax Pharmaceuticals IncQ4 2024 Syndax Pharmaceuticals Inc Earnings CallMar 03, 20

Strengths: Innovative cancer therapies and robust clinical pipeline.Weaknesses: Limited experience in generating revenue from product sales.Opportunities: Expa

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ETCompany ParticipantsSharon Klahre - Head of IRMichael...

The following slide deck was published by Syndax Pharmaceuticals, Inc.

Syndax (SNDX) delivered earnings and revenue surprises of -1.85% and 65.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals Inc (SNDX), a commercial-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ending Dec

Revenue: Achieved $7.7 million in net product revenue for Revuforj in the initial five weeks of its U.S. launch.EPS: Reported a net loss per share of $1.10, mi

Syndax Pharmaceuticals press release (SNDX): Q4 GAAP EPS of -$1.10 misses by $0.28. Revenue of $7.68M misses by $78.83M. Financial Guidance For the first quarter of 2025, the company

Syndax Pharmaceuticals (SNDX) to report Q4 earnings on March 3. Explore EPS growth, revenue forecasts, and recent estimate revisions.

Syndax Pharmaceuticals Inc (SNDX) is set to release its Q4 2024 earnings on Mar 3, 2025. The consensus estimate for Q4 2024 revenue is $85.91 million, and the e

Syndax Pharmaceuticals Inc (SNDX), a commercial-stage biopharmaceutical company focused on developing innovative cancer therapies, has announced that it will re

**media[548309]**

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals ( SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeli

On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,677,075 shares of Syndax

On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) made a significant move by acquiring an additional 3,257,863 shares of enGene Holdings In

On December 31, 2024, Kynam Capital Management, LP (Trades, Portfolio) executed a significant transaction involving the reduction of its holdings in Dynavax Tec

Overview of StemPoint Capital LP (Trades, Portfolio)'s Recent Transaction On December 31, 2024, StemPoint Capital LP (Trades, Portfolio) executed a strategic tr

On December 31, 2024, StemPoint Capital LP (Trades, Portfolio) executed a noteworthy transaction by acquiring an additional 481,700 shares of Vistagen Therapeut

On December 31, 2024, Eversept Partners, LP (Trades, Portfolio) executed a significant reduction in its holdings of Community Health Systems Inc (CYH). The firm